VivoSim Labs, Inc.
NASDAQ
Real-time Data
01:30 PM
Day's Range
0.520052 wk Range
0.5200Key Statistics
Symbol
VIVS
Name
VivoSim Labs, Inc.
Currency
USD
Exchange
NASDAQ
High
0.60000002
Low
0.51999998
Open
‪0.5700‬
Last
‪0.5800‬
Market Cap
2.02M
Pe Ratio
‪0.47‬
Volume
3.79M
Average Volume
13.25M
Dividend Yield
‪0.00%‬
Change
-0.03
Percent Change
-4.92
Timestamp
2026-07-17
Close
0.57999998
Today Range Start
‪0.5200‬
Today Range End
‪0.6000‬
52 Week Range Start
‪0.5200‬
52 Week Range End
‪5.30‬
Type
Stocks
Country
United States
Compliance - VIVS - VivoSim Labs, Inc.
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-17
Business Screen
COMPLIANT
Financial Screen
NON_COMPLIANT
Compliant Revenue
‪97.00%‬
Non Compliant Revenue
‪2.00%‬
Questionable Revenue
‪1.00%‬
Securities To Market Cap Ratio
‪50.00%‬
Debt To Market Cap Ratio
‪90.00%‬
Historical Data - VIVS - VivoSim Labs, Inc.
Historical Data
Market Cap - VIVS - VivoSim Labs, Inc.
Market Cap
2026-07-17
2.02M
2026-07-16
1.77M
2026-07-15
2.46M
2026-07-14
2.41M
2026-07-13
2.34M
2026-07-10
2.54M
2026-07-09
2.31M
2026-07-08
2.26M
2026-07-07
2.61M
2026-07-06
2.85M
Splits - VIVS - VivoSim Labs, Inc.
Splits
2025-03-21
1-for-12 split (12)
Earnings - VIVS - VivoSim Labs, Inc.
Earnings
Balance Sheet - VIVS - VivoSim Labs, Inc.
Balance Sheet
| Period Ending | 2025-03-31 | 2024-03-31 |
|---|---|---|
 Assets | 14.65M | 6.34M |
| Liabilities | 4.15M | 2.74M |
| Shareholders Equity | 10.49M | 3.60M |
Cash Flow - VIVS - VivoSim Labs, Inc.
Cash Flow
| Period Ending | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Operating Activities | - | - |
| Investing Activities | - | - |
| Financing Activities | - | - |
| End Cash Position | 11.45M | 3.04M |
| Income Tax Paid | 2K | 2K |
| Interest Paid | 10K | - |
| Free Cash Flow | -9.47M | -14.69M |
Income Statement - VIVS - VivoSim Labs, Inc.
Income Statement
| Period Ending | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Sales | 144K | 109K |
| Cost of Goods | 5K | - |
| Gross Profit | 139K | - |
| Operating Expense | - | - |
| Operating Income | -12.61M | -15.08M |
| Non-Operating Interest | - | - |
| Other Income Expense | 10M | 12K |
| Pre Tax Income | -2.48M | -14.66M |
| Income Tax | 2K | 2K |
| Net Income | -2.48M | -14.67M |
| EPS Basic | -1.7 | -19.2 |
| EPS Diluted | -1.7 | -19.2 |
| Basic Shares Outstanding | 1.46M | 762.07K |
| Diluted Shares Outstanding | 1.46M | 762.07K |
| Ebit | -2.47M | -15.08M |
| Ebitda | -12.21M | -14.81M |
| Net Income Continuous Operations | -2.48M | -14.67M |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
Profile - VIVS - VivoSim Labs, Inc.
Profile
Mic Code
XNCM
Sector
Healthcare
Industry
Biotechnology
Employees
14
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company specializing in the testing of drugs and drug candidates using advanced three-dimensional (3D) human tissue models of the liver and intestine. The company employs proprietary new approach methodologies (NAM) to provide detailed insights into liver and intestinal toxicology, aiding pharmaceutical and biotech partners in investigational toxicology, mechanism of drug action elucidation, and prediction of side effect profiles during drug development. VivoSim Labs builds functional 3D human tissues that closely mimic native tissue composition, architecture, and function, including disease states, utilizing high-throughput systems, bioprinting, and flow/stretch-capable technologies. Formerly known as Organovo Holdings, Inc., the company was renamed in April 2025 and has its headquarters in San Diego, California. VivoSim Labs plays a significant role in advancing drug safety and efficacy testing through sophisticated tissue engineering and predictive toxicology platforms, contributing to improved preclinical evaluation in the healthcare biotechnology sector.
Profile Details
Type
Common Stock
Address
11555 Sorrento Valley Road
City
San Diego
State
CA
Zip
92121
Country
United States
Phone
858 224 1000
